Valneva SE (EPA:VLA)
4.168
-0.178 (-4.10%)
Oct 20, 2025, 2:45 PM CET
Valneva SE Revenue
Valneva SE had revenue of 48.33 million EUR in the quarter ending June 30, 2025, with 26.98% growth. This brings the company's revenue in the last twelve months to 196.33 million, up 25.47% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58 million with 10.32% growth.
Revenue (ttm)
196.33M
Revenue Growth
+25.47%
P/S Ratio
3.80
Revenue / Employee
280.47K
Employees
713
Market Cap
746.34M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sanofi | 45.74B |
EssilorLuxottica Société anonyme | 27.24B |
Eurofins Scientific SE | 7.14B |
emeis Société anonyme | 5.77B |
Clariane SE | 5.31B |
bioMérieux | 4.12B |
Ipsen | 3.76B |
Sartorius Stedim Biotech | 2.95B |
Valneva SE News
- 2 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 6 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 11 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 13 days ago - Valneva SE (VALN) Lowers 2025 Sales Forecast Amid Vaccine Setback - GuruFocus
- 13 days ago - Valneva lowers 2025 financial outlook due to loss of Ixchiq vaccine marketing - Seeking Alpha
- 13 days ago - Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates - GlobeNewsWire
- 17 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 20 days ago - Valneva Reports Strong Four-Year Antibody Persistence For Chikungunya Vaccine IXCHIQ - Nasdaq